Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Russian chemists synthesize silver compounds that outperform main tuberculosis drug Three-out-of-five new silver complexes show higher activity against tuberculosis bacteria than rifampicin — the frontline antibiotic One compound completely kills the bacteria, and doesn't just stops their growth 🔸 It uses myrtenic acid and attacks two key targets: cell...

SputnikInt's profile picture

Sputnik

500,020 subscribers

11,938 Aufrufe • vor 1 Monat •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

🚨 SCIENTISTS MAY HAVE FOUND A NEW WAY TO KILL DRUG-RESISTANT BACTERIA. And it doesn't rely on traditional antibiotics. Researchers repurposed a ruthenium-based anticancer drug and activated it using ultrasound deep inside infected tissue. Why this matters: • Antibiotic resistance is one of the fastest-growing threats to global health • Drug-resistant infections could kill more people than cancer by 2050 • Many antibiotics are losing effectiveness • Deep-tissue infections are difficult to target safely • Bacteria continue evolving resistance to conventional treatments The breakthrough: Scientists used a compound called TLD1433, originally developed for cancer therapy. By itself, the drug is largely inactive. But when exposed to focused ultrasound... it generates highly reactive oxygen molecules that attack bacterial DNA and destroy protective biofilms. Unlike antibiotics, the treatment doesn't target a single bacterial pathway. Instead, it creates widespread oxidative damage that bacteria struggle to evolve resistance against. The results were remarkable: • Outperformed conventional antibiotics in laboratory tests • Reduced survival of pneumonia-causing bacteria to just 14% • Broke down oxygen-starved bacterial biofilms • In animal studies, every treated mouse survived • Only 25% of untreated controls survived The deeper implication is enormous: For decades we've searched for new antibiotics. But the future may not be finding stronger drugs. It may be activating existing drugs only where they're needed. By combining chemistry with precisely targeted ultrasound... scientists could attack dangerous infections deep inside the body while minimizing damage to healthy tissue. The real question is: Could sound become one of medicine's most powerful weapons against antibiotic resistance? Follow for more frontier science and technology discoveries.
0:10

🚨 SCIENTISTS MAY HAVE FOUND A NEW WAY TO KILL DRUG-RESISTANT BACTERIA. And it doesn't rely on traditional antibiotics. Researchers repurposed a ruthenium-based anticancer drug and activated it using ultrasound deep inside infected tissue. Why this matters: • Antibiotic resistance is one of the fastest-growing threats to global health • Drug-resistant infections could kill more people than cancer by 2050 • Many antibiotics are losing effectiveness • Deep-tissue infections are difficult to target safely • Bacteria continue evolving resistance to conventional treatments The breakthrough: Scientists used a compound called TLD1433, originally developed for cancer therapy. By itself, the drug is largely inactive. But when exposed to focused ultrasound... it generates highly reactive oxygen molecules that attack bacterial DNA and destroy protective biofilms. Unlike antibiotics, the treatment doesn't target a single bacterial pathway. Instead, it creates widespread oxidative damage that bacteria struggle to evolve resistance against. The results were remarkable: • Outperformed conventional antibiotics in laboratory tests • Reduced survival of pneumonia-causing bacteria to just 14% • Broke down oxygen-starved bacterial biofilms • In animal studies, every treated mouse survived • Only 25% of untreated controls survived The deeper implication is enormous: For decades we've searched for new antibiotics. But the future may not be finding stronger drugs. It may be activating existing drugs only where they're needed. By combining chemistry with precisely targeted ultrasound... scientists could attack dangerous infections deep inside the body while minimizing damage to healthy tissue. The real question is: Could sound become one of medicine's most powerful weapons against antibiotic resistance? Follow for more frontier science and technology discoveries.

TheNewPhysics

10,651 Aufrufe • vor 2 Monaten

🚨 SCIENTISTS JUST CREATED A WAY TO KILL ANTIBIOTIC-RESISTANT BACTERIA USING NOTHING BUT LIGHT. Researchers have developed graphene quantum dots that destroy over 99.9% of antibiotic-resistant S. aureus and E. coli when hit with low-intensity blue light without using any antibiotics at all. The dots work by generating reactive oxygen species that rip apart bacterial cells. After chemically modifying them, the team made the dots over 20 times more efficient, allowing them to work at very low concentrations. Because they’re made from graphene instead of toxic heavy metals, they’re also much safer for medical use. Why this matters: • Antibiotic resistance is one of the fastest-growing threats to global health • This offers a completely different weapon light instead of drugs • The dots could be used in wound dressings, creams, gels, and coatings for implants and catheters • Graphene is cheap, stable, and biocompatible The deeper implication: We’re running out of effective antibiotics, and bacteria are evolving faster than we can develop new drugs. This approach flips the script: instead of fighting bacteria with chemicals they can eventually resist, we use light to trigger a physical attack they can’t easily adapt to. If this scales, it could become a powerful new tool in the fight against superbugs especially for wound infections and medical devices, where resistant bacteria are hardest to treat. Sometimes the solution isn’t a better drug. It’s a better way to attack. Would you trust a light-activated treatment over traditional antibiotics if it worked this well? Follow for more frontier nanotechnology and breakthroughs in the fight against antibiotic resistance.
0:10

🚨 SCIENTISTS JUST CREATED A WAY TO KILL ANTIBIOTIC-RESISTANT BACTERIA USING NOTHING BUT LIGHT. Researchers have developed graphene quantum dots that destroy over 99.9% of antibiotic-resistant S. aureus and E. coli when hit with low-intensity blue light without using any antibiotics at all. The dots work by generating reactive oxygen species that rip apart bacterial cells. After chemically modifying them, the team made the dots over 20 times more efficient, allowing them to work at very low concentrations. Because they’re made from graphene instead of toxic heavy metals, they’re also much safer for medical use. Why this matters: • Antibiotic resistance is one of the fastest-growing threats to global health • This offers a completely different weapon light instead of drugs • The dots could be used in wound dressings, creams, gels, and coatings for implants and catheters • Graphene is cheap, stable, and biocompatible The deeper implication: We’re running out of effective antibiotics, and bacteria are evolving faster than we can develop new drugs. This approach flips the script: instead of fighting bacteria with chemicals they can eventually resist, we use light to trigger a physical attack they can’t easily adapt to. If this scales, it could become a powerful new tool in the fight against superbugs especially for wound infections and medical devices, where resistant bacteria are hardest to treat. Sometimes the solution isn’t a better drug. It’s a better way to attack. Would you trust a light-activated treatment over traditional antibiotics if it worked this well? Follow for more frontier nanotechnology and breakthroughs in the fight against antibiotic resistance.

TheNewPhysics

35,112 Aufrufe • vor 2 Monaten

🇺🇦🇷🇺UKRAINE SAYS A NEW LASER WEAPON COULD ENTER SERVICE WITHIN MONTHS. Deputy Commander-in-Chief of the Armed Forces of Ukraine Andrii Lebedenko says Kyiv expects to field a laser system capable of destroying aerial targets more effectively than machine guns within the next two to three months. The new directed-energy weapon is designed to intercept drones and other airborne threats with far greater precision, speed, and efficiency than conventional gun-based systems. If deployed successfully, the system could significantly strengthen Ukraine’s short-range air defense network, reducing ammunition costs and giving frontline units a powerful new tool against increasingly frequent drone attacks. Video is AI
0:15

🇺🇦🇷🇺UKRAINE SAYS A NEW LASER WEAPON COULD ENTER SERVICE WITHIN MONTHS. Deputy Commander-in-Chief of the Armed Forces of Ukraine Andrii Lebedenko says Kyiv expects to field a laser system capable of destroying aerial targets more effectively than machine guns within the next two to three months. The new directed-energy weapon is designed to intercept drones and other airborne threats with far greater precision, speed, and efficiency than conventional gun-based systems. If deployed successfully, the system could significantly strengthen Ukraine’s short-range air defense network, reducing ammunition costs and giving frontline units a powerful new tool against increasingly frequent drone attacks. Video is AI

NSTRIKE

88,125 Aufrufe • vor 26 Tagen

Folks, right now, 25 of the largest pharmaceutical companies in America control 70% of the market. This lack of competition drives up prices – making it harder for hardworking American families to access the health care they need. Today, my Administration is doing something about it. Let me explain: Hundreds of billions of taxpayer dollars are spent on research, discovery, and development of new prescription drugs. And while I firmly believe that the strength of a nation can be measured by the boldness of its science, the quality of its research, and the progress it helps bring forth, I also believe that the folks who paid for the research – you – ought to be able to access and afford the final product. That's why my Administration is proposing that if a drug made using taxpayer funds is not reasonably available to Americans, the government reserves the right to "march in" and license that drug to another manufacturer who could sell it for less. This is an important step toward ending Big Pharma price gouging. It's good for competition. It's good for our economy. And it's good for the millions of Americans who can't afford their medications – who know all too well that fine line between dignity and dependence that the price of a prescription drug can draw.
0:15

Folks, right now, 25 of the largest pharmaceutical companies in America control 70% of the market. This lack of competition drives up prices – making it harder for hardworking American families to access the health care they need. Today, my Administration is doing something about it. Let me explain: Hundreds of billions of taxpayer dollars are spent on research, discovery, and development of new prescription drugs. And while I firmly believe that the strength of a nation can be measured by the boldness of its science, the quality of its research, and the progress it helps bring forth, I also believe that the folks who paid for the research – you – ought to be able to access and afford the final product. That's why my Administration is proposing that if a drug made using taxpayer funds is not reasonably available to Americans, the government reserves the right to "march in" and license that drug to another manufacturer who could sell it for less. This is an important step toward ending Big Pharma price gouging. It's good for competition. It's good for our economy. And it's good for the millions of Americans who can't afford their medications – who know all too well that fine line between dignity and dependence that the price of a prescription drug can draw.

President Biden Archived

1,851,715 Aufrufe • vor 2 Jahren

LG Manoj Sinha's Nasha Mukti campaign has evolved into one of the largest people's movements in Jammu & Kashmir. After personally visiting every district in the Kashmir Valley and joining padyatras across the region, LG Manoj Sinha declared that a historic movement against narco-terrorism has risen. The results speak for themselves: in just 55 days, 1,036 FIRs have been registered, 1,128 drug smugglers arrested, more than 100 properties attached, nearly 700 driving licences cancelled and recommendations made to revoke 130 passports. While strict action is being taken against narco-terrorists, rehabilitation and new opportunities are also being extended to those trapped in addiction. A strong message has gone out—drug peddlers and narco-terrorists will find no refuge in Jammu & Kashmir. #JKFightsDrugs #JKDefeatsDrugs
0:28

LG Manoj Sinha's Nasha Mukti campaign has evolved into one of the largest people's movements in Jammu & Kashmir. After personally visiting every district in the Kashmir Valley and joining padyatras across the region, LG Manoj Sinha declared that a historic movement against narco-terrorism has risen. The results speak for themselves: in just 55 days, 1,036 FIRs have been registered, 1,128 drug smugglers arrested, more than 100 properties attached, nearly 700 driving licences cancelled and recommendations made to revoke 130 passports. While strict action is being taken against narco-terrorists, rehabilitation and new opportunities are also being extended to those trapped in addiction. A strong message has gone out—drug peddlers and narco-terrorists will find no refuge in Jammu & Kashmir. #JKFightsDrugs #JKDefeatsDrugs

Megh Updates 🚨™

91,990 Aufrufe • vor 2 Monaten

BREAKING: President Donald J. Trump just signed an executive order implementing Most Favored Nation prescription drug pricing — which will deliver dramatically lower drug prices for the American people. Here's what it does: REDUCING DRUG PRICES FOR AMERICANS AND TAXPAYERS: Today, President Donald J. Trump signed an Executive Order to bring the prices Americans and taxpayers pay for prescription drugs in line with those paid by similar nations. — The Order directs the U.S. Trade Representative and Secretary of Commerce to take action to ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States. — The Order instructs the Administration to communicate price targets to pharmaceutical manufacturers to establish that America, the largest purchaser and funder of prescription drugs in the world, gets the best deal. — The Secretary of Health and Human Services will establish a mechanism through which American patients can buy their drugs directly from manufacturers who sell to Americans at a “Most-Favored-Nation” price, bypassing middlemen. — If drug manufacturers fail to offer most-favored-nation pricing, the Order directs the Secretary of Health and Human Services to: (1) propose rules that impose most-favored-nation pricing; and (2) take other aggressive measures to significantly reduce the cost of prescription drugs to the American consumer and end anticompetitive practices. GETTING A BETTER DEAL FOR AMERICANS: President Trump is once again taking action to keep pharmaceutical manufacturers from charging Americans high drug prices while giving steep discounts to other wealthy nations. — According to recent data, the prices Americans pay for brand-name drugs are more than three times the price other OECD nations pay, even after accounting for discounts manufacturers provide in the U.S. — The United States has less than five percent of the world’s population, yet funds roughly 75% of global pharmaceutical profits. — Drug manufacturers discount their products to gain access to foreign markets and then subsidize those discounts through high prices charged in America—in essence, Americans are subsidizing drug-manufacturer profits and foreign health systems, despite drug manufacturers benefiting from generous research subsidies and enormous healthcare spending by the U.S. Government. — In his first term, President Trump took historic action to keep Medicare and seniors from paying more for drugs than economically comparable countries, which the Biden Administration rescinded before it could take effect. — Instead of fixing this problem, the Biden Administration’s greatest achievement was to negotiate prices that were, on average, 78 percent higher than in 11 comparable countries as part of Biden’s effort to “beat Medicare.” DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on his promise to once again put America first by furthering efforts to get American patients and taxpayers a fair deal for prescription drugs. — This Order builds on actions from President Trump’s first term to make progress on reducing price disparities at home and expands those efforts by including Medicaid in addition to Medicare. — President Trump recently signed an Executive Order to take additional action to lower drug prices, including by providing massive discounts to low-income patients for lifesaving medicines, facilitating importation programs, and increasing the availability of generic and biosimilar medicines. — President Trump is also working to make drug prices radically transparent, as he recently signed an Executive Order to build on his historic price transparency efforts undertaken during his first term. — President Trump has been relentless in his effort to address the unfair and outrageous prices Americans pay for prescription drugs: — President Trump: “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”
0:13

BREAKING: President Donald J. Trump just signed an executive order implementing Most Favored Nation prescription drug pricing — which will deliver dramatically lower drug prices for the American people. Here's what it does: REDUCING DRUG PRICES FOR AMERICANS AND TAXPAYERS: Today, President Donald J. Trump signed an Executive Order to bring the prices Americans and taxpayers pay for prescription drugs in line with those paid by similar nations. — The Order directs the U.S. Trade Representative and Secretary of Commerce to take action to ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States. — The Order instructs the Administration to communicate price targets to pharmaceutical manufacturers to establish that America, the largest purchaser and funder of prescription drugs in the world, gets the best deal. — The Secretary of Health and Human Services will establish a mechanism through which American patients can buy their drugs directly from manufacturers who sell to Americans at a “Most-Favored-Nation” price, bypassing middlemen. — If drug manufacturers fail to offer most-favored-nation pricing, the Order directs the Secretary of Health and Human Services to: (1) propose rules that impose most-favored-nation pricing; and (2) take other aggressive measures to significantly reduce the cost of prescription drugs to the American consumer and end anticompetitive practices. GETTING A BETTER DEAL FOR AMERICANS: President Trump is once again taking action to keep pharmaceutical manufacturers from charging Americans high drug prices while giving steep discounts to other wealthy nations. — According to recent data, the prices Americans pay for brand-name drugs are more than three times the price other OECD nations pay, even after accounting for discounts manufacturers provide in the U.S. — The United States has less than five percent of the world’s population, yet funds roughly 75% of global pharmaceutical profits. — Drug manufacturers discount their products to gain access to foreign markets and then subsidize those discounts through high prices charged in America—in essence, Americans are subsidizing drug-manufacturer profits and foreign health systems, despite drug manufacturers benefiting from generous research subsidies and enormous healthcare spending by the U.S. Government. — In his first term, President Trump took historic action to keep Medicare and seniors from paying more for drugs than economically comparable countries, which the Biden Administration rescinded before it could take effect. — Instead of fixing this problem, the Biden Administration’s greatest achievement was to negotiate prices that were, on average, 78 percent higher than in 11 comparable countries as part of Biden’s effort to “beat Medicare.” DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on his promise to once again put America first by furthering efforts to get American patients and taxpayers a fair deal for prescription drugs. — This Order builds on actions from President Trump’s first term to make progress on reducing price disparities at home and expands those efforts by including Medicaid in addition to Medicare. — President Trump recently signed an Executive Order to take additional action to lower drug prices, including by providing massive discounts to low-income patients for lifesaving medicines, facilitating importation programs, and increasing the availability of generic and biosimilar medicines. — President Trump is also working to make drug prices radically transparent, as he recently signed an Executive Order to build on his historic price transparency efforts undertaken during his first term. — President Trump has been relentless in his effort to address the unfair and outrageous prices Americans pay for prescription drugs: — President Trump: “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”

Rapid Response 47

611,256 Aufrufe • vor 1 Jahr

The significance of LG Manoj Sinha's Nasha Mukt Jammu & Kashmir Abhiyaan lies not just in the numbers, but in the message it has sent across the Union Territory. For decades, drugs silently destroyed families, ruined young lives and provided a funding channel for anti-national forces. Today, that silence has been broken. From Jammu to Ganderbal, LG Manoj Sinha has mobilized citizens, students, mothers, teachers and community leaders into a united front against narco-terrorism. Having personally visited every district in the Kashmir Valley and marched alongside the people, he has transformed the fight against drugs into a grassroots movement. The campaign's achievements in just 55 days are unprecedented—over 1,000 FIRs, more than 1,100 drug smugglers arrested, over 100 properties attached and hundreds of licences cancelled. Yet its larger success lies in changing public consciousness. LG Manoj Sinha has repeatedly warned that drug trafficking is not merely a criminal enterprise but a direct threat to national security, with narcotics profits often used to fuel terrorism. His unwavering commitment to both strict action against smugglers and rehabilitation for victims is creating a new framework where enforcement, awareness and social responsibility work together to secure the future of Jammu & Kashmir. #JKFightsDrugs #JKDefeatsDrugs
0:06

The significance of LG Manoj Sinha's Nasha Mukt Jammu & Kashmir Abhiyaan lies not just in the numbers, but in the message it has sent across the Union Territory. For decades, drugs silently destroyed families, ruined young lives and provided a funding channel for anti-national forces. Today, that silence has been broken. From Jammu to Ganderbal, LG Manoj Sinha has mobilized citizens, students, mothers, teachers and community leaders into a united front against narco-terrorism. Having personally visited every district in the Kashmir Valley and marched alongside the people, he has transformed the fight against drugs into a grassroots movement. The campaign's achievements in just 55 days are unprecedented—over 1,000 FIRs, more than 1,100 drug smugglers arrested, over 100 properties attached and hundreds of licences cancelled. Yet its larger success lies in changing public consciousness. LG Manoj Sinha has repeatedly warned that drug trafficking is not merely a criminal enterprise but a direct threat to national security, with narcotics profits often used to fuel terrorism. His unwavering commitment to both strict action against smugglers and rehabilitation for victims is creating a new framework where enforcement, awareness and social responsibility work together to secure the future of Jammu & Kashmir. #JKFightsDrugs #JKDefeatsDrugs

Jassi

24,816 Aufrufe • vor 2 Monaten

🚨 SCIENTISTS JUST DISCOVERED THAT BACTERIA HAVE BEEN USING A QUANTUM ENERGY TRICK FOR BILLIONS OF YEARS. In a breakthrough published in Nature Chemistry, researchers from the University of Sheffield (working with IBM and international collaborators) have shown that purple photosynthetic bacteria (Rhodobacter sphaeroides) use singlet fission (SF) as a functional mechanism to enhance light harvesting. When carotenoids absorb blue-green light (via their S₂ state), the energy rapidly undergoes heterofission: the singlet exciton splits into a pair of triplet excitons shared between a carotenoid and its neighboring bacteriochlorophyll (BChl) a molecule. These triplet pairs are long-lived and weakly coupled. They then recombine via triplet-triplet annihilation (TTA), efficiently populating the BChl a Qy singlet state which then transfers energy to the reaction center. This SF-mediated pathway contributes up to ~18% of total carotenoid-to-BChl energy transfer in some complexes and introduces a temporal “buffering” effect, staggering energy arrival at the reaction center. Why this matters: • It is the clearest demonstration yet that singlet fission plays a genuine, functional role in natural photosynthesis • The heterofission mechanism (triplets on adjacent Crt and BChl molecules) explains how bacteria achieve ultrafast SF while maintaining long-lived, harvestable triplet pairs • This pathway helps organisms make better use of blue-green light and may protect the reaction center during fluctuating light conditions The deeper implication: Nature has evolved a sophisticated way to temporarily store and then cooperatively release electronic energy using spin-protected triplet states. This biological strategy offers new inspiration for designing artificial light-harvesting and energy-conversion systems that can buffer and regulate energy flow something synthetic SF materials have struggled to achieve. We are learning that evolution solved some of the hardest problems in photophysics long before we started trying. How might understanding biological singlet fission change the way we design future solar energy or quantum-inspired technologies? Follow for more frontier photosynthesis research and natural quantum biology.
0:10

🚨 SCIENTISTS JUST DISCOVERED THAT BACTERIA HAVE BEEN USING A QUANTUM ENERGY TRICK FOR BILLIONS OF YEARS. In a breakthrough published in Nature Chemistry, researchers from the University of Sheffield (working with IBM and international collaborators) have shown that purple photosynthetic bacteria (Rhodobacter sphaeroides) use singlet fission (SF) as a functional mechanism to enhance light harvesting. When carotenoids absorb blue-green light (via their S₂ state), the energy rapidly undergoes heterofission: the singlet exciton splits into a pair of triplet excitons shared between a carotenoid and its neighboring bacteriochlorophyll (BChl) a molecule. These triplet pairs are long-lived and weakly coupled. They then recombine via triplet-triplet annihilation (TTA), efficiently populating the BChl a Qy singlet state which then transfers energy to the reaction center. This SF-mediated pathway contributes up to ~18% of total carotenoid-to-BChl energy transfer in some complexes and introduces a temporal “buffering” effect, staggering energy arrival at the reaction center. Why this matters: • It is the clearest demonstration yet that singlet fission plays a genuine, functional role in natural photosynthesis • The heterofission mechanism (triplets on adjacent Crt and BChl molecules) explains how bacteria achieve ultrafast SF while maintaining long-lived, harvestable triplet pairs • This pathway helps organisms make better use of blue-green light and may protect the reaction center during fluctuating light conditions The deeper implication: Nature has evolved a sophisticated way to temporarily store and then cooperatively release electronic energy using spin-protected triplet states. This biological strategy offers new inspiration for designing artificial light-harvesting and energy-conversion systems that can buffer and regulate energy flow something synthetic SF materials have struggled to achieve. We are learning that evolution solved some of the hardest problems in photophysics long before we started trying. How might understanding biological singlet fission change the way we design future solar energy or quantum-inspired technologies? Follow for more frontier photosynthesis research and natural quantum biology.

TheNewPhysics

75,999 Aufrufe • vor 1 Monat

Some microbes carry a protein, called SNIPE, that "chops up" phage DNA as it's being injected into the cell. This is a new mechanism for phage defense! CRISPR–Cas and restriction enzymes also evolved to fight against phages, but they work by recognizing sequences. SNIPE works, instead, by sensing "touch." SNIPE is a protein with about 500 amino acids. After it's made by the ribosome, it latches onto ManYZ, two proteins which sit on the cell's inner membrane. (ManYZ is an importer; it brings mannose and other sugars into the cell.) Once attached to ManYZ, SNIPE sits and waits for an invading phage. Some phages, including lambda, actually infect cells by pushing their DNA through this ManYZ channel. Lambda uses its "tail" to reach inside the protein channel, basically, and inject its DNA. When this physical touch happens, though, SNIPE is waiting. As soon as the phage DNA starts entering the cell, and passes through ManYZ and SNIPE, it gets immediately destroyed. This means that SNIPE is the first phage defense system discovered, so far, that uses spatial positioning at the injection site to destroy invaders. But there are caveats, of course. If you untether SNIPE from ManYZ, such that it can freely diffuse through the cell, it will chew up the bacterium's genome. It is not a highly discerning nuclease! Also, SNIPE is not found in most bacteria. A prior pangenome study, which sequenced lots of different microbes, found that roughly a third of well-studied bacterial lineages had at least one member with a SNIPE-like protein. (For this paper, they just ported one of those homologs into an E. coli laboratory strain.) And finally, because SNIPE's mechanism is tightly tied to ManYZ, it cannot be used to defend against phages that enter the cell through different routes. T4 phages, for example, inject their DNA straight through the cell membrane and into the cytoplasm, without interacting with ManYZ. This is a nice basic science paper. Applications TBD. (Just remember that scientists figured out that bacteria had a phage defense system, called CRISPR-Cas, many years before it was repurposed into a gene-editing tool.) P.S. The video below shows how cells with the SNIPE gene (middle row) kill invading phages, and thus continue growing and dividing. Empty vector (top row) refers to bacteria carrying a plasmid with no SNIPE gene; this is a control group. And SNIPE E414A refers to cells which received a mutated SNIPE gene, where the glutamate at position 414 has been changed to an alanine, thus destroying the protein's nuclease activity. These cells also die when they get infected with a phage.
0:10

Some microbes carry a protein, called SNIPE, that "chops up" phage DNA as it's being injected into the cell. This is a new mechanism for phage defense! CRISPR–Cas and restriction enzymes also evolved to fight against phages, but they work by recognizing sequences. SNIPE works, instead, by sensing "touch." SNIPE is a protein with about 500 amino acids. After it's made by the ribosome, it latches onto ManYZ, two proteins which sit on the cell's inner membrane. (ManYZ is an importer; it brings mannose and other sugars into the cell.) Once attached to ManYZ, SNIPE sits and waits for an invading phage. Some phages, including lambda, actually infect cells by pushing their DNA through this ManYZ channel. Lambda uses its "tail" to reach inside the protein channel, basically, and inject its DNA. When this physical touch happens, though, SNIPE is waiting. As soon as the phage DNA starts entering the cell, and passes through ManYZ and SNIPE, it gets immediately destroyed. This means that SNIPE is the first phage defense system discovered, so far, that uses spatial positioning at the injection site to destroy invaders. But there are caveats, of course. If you untether SNIPE from ManYZ, such that it can freely diffuse through the cell, it will chew up the bacterium's genome. It is not a highly discerning nuclease! Also, SNIPE is not found in most bacteria. A prior pangenome study, which sequenced lots of different microbes, found that roughly a third of well-studied bacterial lineages had at least one member with a SNIPE-like protein. (For this paper, they just ported one of those homologs into an E. coli laboratory strain.) And finally, because SNIPE's mechanism is tightly tied to ManYZ, it cannot be used to defend against phages that enter the cell through different routes. T4 phages, for example, inject their DNA straight through the cell membrane and into the cytoplasm, without interacting with ManYZ. This is a nice basic science paper. Applications TBD. (Just remember that scientists figured out that bacteria had a phage defense system, called CRISPR-Cas, many years before it was repurposed into a gene-editing tool.) P.S. The video below shows how cells with the SNIPE gene (middle row) kill invading phages, and thus continue growing and dividing. Empty vector (top row) refers to bacteria carrying a plasmid with no SNIPE gene; this is a control group. And SNIPE E414A refers to cells which received a mutated SNIPE gene, where the glutamate at position 414 has been changed to an alanine, thus destroying the protein's nuclease activity. These cells also die when they get infected with a phage.

Niko McCarty.

20,536 Aufrufe • vor 5 Monaten

A single E. coli cell, placed on a dish, will become 70 billion cells in just 12 hours. That’s exponential growth. But a new preprint shows that it's possible to engineer E. coli to grow linearly instead, where only one daughter cell continues dividing and the other stops. First, some context. In nature, there is a bacterium called Mycobacterium smegmatis (initially discovered in 1884 in ulcers scraped from syphilis patients.) M. smegmatis is weird because it divides asymmetrically. These cells grow only from one end, and all their cell wall biosynthesis machinery is located on that one end. So when the cell divides, one daughter gets this machinery and the other gets nothing. The daughter that gets the machinery can keep dividing immediately, but the other daughter has to remake all that machinery from scratch, so its growth is delayed. E. coli doesn’t grow like this. When it divides, it pinches in the middle and splits everything evenly. Enzymes, metabolites, and proteins get partitioned more or less randomly between the two daughters. For the new preprint, though, researchers engineered E. coli to behave more like M. smegmatis. Here is how they did it: First, they deleted a gene called cyaA, which encodes an enzyme (adenylate cyclase) that makes a molecule called cAMP. cAMP is SUPER IMPORTANT! It is a nutrient sensor that instructs E. coli to switch on genes that help it digest non-glucose carbon sources when glucose is scarce. Without cAMP, E. coli cells growing on alternative carbon sources will starve; they won’t know how to eat the food. Next, they added back a “split” version of the cyaA gene into the cells. In other words, they split the gene in two so that each half of the enzyme is made separately. Cells can only make cAMP, and thus eat non-glucose carbon sources, if these two halves come together. To facilitate that “coming together,” the researchers also fused the split cyaA proteins to sticky proteins that clump together, and to a fluorescent protein (to make it easy to track these molecules in the cell.) So now some interesting things start to happen if you grow E. coli on a growth medium lacking glucose. As the cell grows, its cyaA “halves” start clumping together into a giant ball. Inside the aggregate, the two enzyme halves come together and make cAMP. And when the cell gets big enough and divides, the clump of cyaA RANDOMLY goes to either daughter cell #1 or #2. The daughter that gets the aggregate (called PA+ in this paper) can keep dividing. The daughter that doesn’t (PA–) cannot. It still grows a few times — about four divisions — because it inherits some leftover cAMP from its mother. But after that, the metabolite is diluted away, and the cell stops growing. PA+ cells went through about 23 divisions on average before their aggregate decayed. And the population of cells, as a whole, grew linearly. This paper is cool because there are many applications where exponential growth is too unpredictable and, perhaps, unsafe. If you want to engineer bacteria to deliver drugs, clean up waste, or live in the gut, you don’t want them to double uncontrollably. This paper shows you can make them expand in a controlled, linear way. Alas, mutations could break this whole engineered system. A mutation that restores cyaA, for example, would give cells a new way to make cAMP. Mutations that make the aggregates split between daughters would break the asymmetry, too. But still, I really enjoy proof-of-concept engineering papers like this.
0:14

A single E. coli cell, placed on a dish, will become 70 billion cells in just 12 hours. That’s exponential growth. But a new preprint shows that it's possible to engineer E. coli to grow linearly instead, where only one daughter cell continues dividing and the other stops. First, some context. In nature, there is a bacterium called Mycobacterium smegmatis (initially discovered in 1884 in ulcers scraped from syphilis patients.) M. smegmatis is weird because it divides asymmetrically. These cells grow only from one end, and all their cell wall biosynthesis machinery is located on that one end. So when the cell divides, one daughter gets this machinery and the other gets nothing. The daughter that gets the machinery can keep dividing immediately, but the other daughter has to remake all that machinery from scratch, so its growth is delayed. E. coli doesn’t grow like this. When it divides, it pinches in the middle and splits everything evenly. Enzymes, metabolites, and proteins get partitioned more or less randomly between the two daughters. For the new preprint, though, researchers engineered E. coli to behave more like M. smegmatis. Here is how they did it: First, they deleted a gene called cyaA, which encodes an enzyme (adenylate cyclase) that makes a molecule called cAMP. cAMP is SUPER IMPORTANT! It is a nutrient sensor that instructs E. coli to switch on genes that help it digest non-glucose carbon sources when glucose is scarce. Without cAMP, E. coli cells growing on alternative carbon sources will starve; they won’t know how to eat the food. Next, they added back a “split” version of the cyaA gene into the cells. In other words, they split the gene in two so that each half of the enzyme is made separately. Cells can only make cAMP, and thus eat non-glucose carbon sources, if these two halves come together. To facilitate that “coming together,” the researchers also fused the split cyaA proteins to sticky proteins that clump together, and to a fluorescent protein (to make it easy to track these molecules in the cell.) So now some interesting things start to happen if you grow E. coli on a growth medium lacking glucose. As the cell grows, its cyaA “halves” start clumping together into a giant ball. Inside the aggregate, the two enzyme halves come together and make cAMP. And when the cell gets big enough and divides, the clump of cyaA RANDOMLY goes to either daughter cell #1 or #2. The daughter that gets the aggregate (called PA+ in this paper) can keep dividing. The daughter that doesn’t (PA–) cannot. It still grows a few times — about four divisions — because it inherits some leftover cAMP from its mother. But after that, the metabolite is diluted away, and the cell stops growing. PA+ cells went through about 23 divisions on average before their aggregate decayed. And the population of cells, as a whole, grew linearly. This paper is cool because there are many applications where exponential growth is too unpredictable and, perhaps, unsafe. If you want to engineer bacteria to deliver drugs, clean up waste, or live in the gut, you don’t want them to double uncontrollably. This paper shows you can make them expand in a controlled, linear way. Alas, mutations could break this whole engineered system. A mutation that restores cyaA, for example, would give cells a new way to make cAMP. Mutations that make the aggregates split between daughters would break the asymmetry, too. But still, I really enjoy proof-of-concept engineering papers like this.

Niko McCarty.

58,047 Aufrufe • vor 11 Monaten

📢 EstateX: The Next Phase Begins This week, we're pulling back the curtain on what we've been building - and announcing the first wave of ecosystem activations. What's Coming This Week: ✅ Multiple Project updates ✅ Concrete dates for key launches ✅ Behind-the-scenes reveals Now that the launch is complete, it’s time for the REAL work and business building to begin. A series of exciting developments are scheduled for release in the near future, including but not limited to: 📊 The Ecosystem Overview: 👇 (All of which will have positive flow use cases and utilities for $ESX) 🔸 20-35% of Company Revenue Buybacks - this amount of revenue generated is used to buy the $ESX token off the market 🔸 Investment Platform Transaction Fees - all transaction fees on the EstateX investment platform are paid in $ESX or used to buy $ESX off the market 🔸 ESX Blockchain Gas Fees – Every transaction fuels the network, increasing $ESX usage and demand. 🔸 RWAPad / Unicorn Club Staking – Creating $ESX lockup and growth pressure. 🔸 Whitelabel Solutions – Platform adoption by other companies drives $ESX circulation and utility. 🔸 PropXChange – Trades in tokenized real estate generate fees that flow back to $ESX. 🔸 EstateX Pay – Card transactions generate revenue that supports $ESX growth. 🔸 CapitalX Lending – Loan and interest fees contribute to $ESX buybacks. 🔸 EstateX University – Access and education fees contribute to $ESX ecosystem growth. 🔸 $AIESX Utilization – Revenue drives $ESX buybacks. 🔸 Real Estate Rental Income – Passive rental flows create consistent $ESX circulation. 🔸 Expansion Into New RWAs – Future tokenized assets add more revenue streams, boosting $ESX demand. 🔸PLUS more surprises to be revealed! 💰 Financial Perspective: Consider just one of these components: real estate tokenization. A $100M AUM (Assets Under Management) portfolio in the first 6 months of operations could generate 10% in revenue from all pillars involved. That's $10M in total revenue. With up to 35% of that revenue allocated to buybacks, that's major buy pressure from a single revenue stream. Now multiply that across the entire ecosystem. But we're doing this RIGHT. That means rolling out strategically, testing thoroughly, and ensuring each piece is bulletproof before launch. 👉 Our new standard: Underpromise, overdeliver on EVERY deadline. This week, you'll see the first glimpses of what EstateX truly is. And this is just the beginning. First announcement drops very soon. The $ESX token is LIVE! Accumulate $ESX 👉 Watch the $ESX use case video now: Join our community 👇
0:12

📢 EstateX: The Next Phase Begins This week, we're pulling back the curtain on what we've been building - and announcing the first wave of ecosystem activations. What's Coming This Week: ✅ Multiple Project updates ✅ Concrete dates for key launches ✅ Behind-the-scenes reveals Now that the launch is complete, it’s time for the REAL work and business building to begin. A series of exciting developments are scheduled for release in the near future, including but not limited to: 📊 The Ecosystem Overview: 👇 (All of which will have positive flow use cases and utilities for $ESX) 🔸 20-35% of Company Revenue Buybacks - this amount of revenue generated is used to buy the $ESX token off the market 🔸 Investment Platform Transaction Fees - all transaction fees on the EstateX investment platform are paid in $ESX or used to buy $ESX off the market 🔸 ESX Blockchain Gas Fees – Every transaction fuels the network, increasing $ESX usage and demand. 🔸 RWAPad / Unicorn Club Staking – Creating $ESX lockup and growth pressure. 🔸 Whitelabel Solutions – Platform adoption by other companies drives $ESX circulation and utility. 🔸 PropXChange – Trades in tokenized real estate generate fees that flow back to $ESX. 🔸 EstateX Pay – Card transactions generate revenue that supports $ESX growth. 🔸 CapitalX Lending – Loan and interest fees contribute to $ESX buybacks. 🔸 EstateX University – Access and education fees contribute to $ESX ecosystem growth. 🔸 $AIESX Utilization – Revenue drives $ESX buybacks. 🔸 Real Estate Rental Income – Passive rental flows create consistent $ESX circulation. 🔸 Expansion Into New RWAs – Future tokenized assets add more revenue streams, boosting $ESX demand. 🔸PLUS more surprises to be revealed! 💰 Financial Perspective: Consider just one of these components: real estate tokenization. A $100M AUM (Assets Under Management) portfolio in the first 6 months of operations could generate 10% in revenue from all pillars involved. That's $10M in total revenue. With up to 35% of that revenue allocated to buybacks, that's major buy pressure from a single revenue stream. Now multiply that across the entire ecosystem. But we're doing this RIGHT. That means rolling out strategically, testing thoroughly, and ensuring each piece is bulletproof before launch. 👉 Our new standard: Underpromise, overdeliver on EVERY deadline. This week, you'll see the first glimpses of what EstateX truly is. And this is just the beginning. First announcement drops very soon. The $ESX token is LIVE! Accumulate $ESX 👉 Watch the $ESX use case video now: Join our community 👇

EstateX

118,910 Aufrufe • vor 8 Monaten

There's a bacteriophage that turns bacteria into “liquid crystals.” Specifically, Pseudomonas aeruginosa bacteria make Pf phages, which are rod-shaped, negatively-charged, and measure about 2 micrometers in length (roughly the length of an E. coli cell). These phages leave the cells and enter their surroundings. There, they mix with polymers, also secreted by the cells, to form a crystalline matrix. Surprisingly, this is good for the cells. Although the phages kill some of them, it also makes their biofilms stickier and able to withstand certain antibiotics. These bacteria + phages are prevalent in cystic fibrosis patients; they've formed a sort of symbiotic relationship. The Pf phages are made from thousands of repeating copies of a coat protein, called CoaB, which wraps around a single-stranded, circular DNA genome. These genes are integrated directly on the bacterial chromosome. The bacteria “turn on” these phage genes when placed in a viscous environment with low oxygen levels. This is like a trigger to start forming a biofilm. And the cells make a lot of phages; about 100 billion per milliliter. These liquid crystals form because of a physics principle called “depletion attraction.” If you just mix a bunch of loose or flexible polymers together (such as long carbon chains) they will not form a liquid crystal. But if you mix stiff rods (the phages) with loose polymers at a high enough concentration, the polymers will force the phages close together to create a material that flows like a liquid despite being ordered like a crystal. See the video below. These liquid crystal biofilms are hard to get rid of. The negatively-charged phages block many antibiotics (like aminoglycosides, which are positively-charged) from entering cells. Liquid crystals also retain water, so these biofilms can survive on drier surfaces. I first heard about this from Malmesbury’s excellent newsletter, called “Telescopic Turnip.”
0:15

There's a bacteriophage that turns bacteria into “liquid crystals.” Specifically, Pseudomonas aeruginosa bacteria make Pf phages, which are rod-shaped, negatively-charged, and measure about 2 micrometers in length (roughly the length of an E. coli cell). These phages leave the cells and enter their surroundings. There, they mix with polymers, also secreted by the cells, to form a crystalline matrix. Surprisingly, this is good for the cells. Although the phages kill some of them, it also makes their biofilms stickier and able to withstand certain antibiotics. These bacteria + phages are prevalent in cystic fibrosis patients; they've formed a sort of symbiotic relationship. The Pf phages are made from thousands of repeating copies of a coat protein, called CoaB, which wraps around a single-stranded, circular DNA genome. These genes are integrated directly on the bacterial chromosome. The bacteria “turn on” these phage genes when placed in a viscous environment with low oxygen levels. This is like a trigger to start forming a biofilm. And the cells make a lot of phages; about 100 billion per milliliter. These liquid crystals form because of a physics principle called “depletion attraction.” If you just mix a bunch of loose or flexible polymers together (such as long carbon chains) they will not form a liquid crystal. But if you mix stiff rods (the phages) with loose polymers at a high enough concentration, the polymers will force the phages close together to create a material that flows like a liquid despite being ordered like a crystal. See the video below. These liquid crystal biofilms are hard to get rid of. The negatively-charged phages block many antibiotics (like aminoglycosides, which are positively-charged) from entering cells. Liquid crystals also retain water, so these biofilms can survive on drier surfaces. I first heard about this from Malmesbury’s excellent newsletter, called “Telescopic Turnip.”

Niko McCarty.

50,095 Aufrufe • vor 7 Monaten

Slow Progress is the New Reality of Modern Wars There are many people commenting on Russian difficulties and coming up with numerous reasons for their alleged collapse. I absolutely do not see any collapse; on the contrary, Russia has already normalized a state of war in Ukraine, which boosts its economic and industrial growth. The difficulties faced by Russia today are the same as at the beginning of the war, with soldiers having to spend up to half of their initial salaries on their own equipment, delays in pensions, and a series of other problems that are mirrored on the Ukrainian side, even with all the support from allies. The war today is much less lethal than it was months ago, and both Russian and Ukrainian losses have significantly decreased during this phase. Lethality has fallen, but Russian advances persist. And why are they slow? Is it a Ukrainian tactic? No. They are slow because they are accompanied by the deployment of communication infrastructure like signal repeaters for drones, the advancement of artillery guided by drones, maneuvers using FAB and more recently ODAB bombs against Ukrainian drone operators' facilities, infiltration by reconnaissance teams, saboteurs, and a series of protocols they have developed. That conventional war with rapid advances no longer exists, and in the context of a battlefield dominated by drones, it is unlikely to return. Modern wars will have slow progress, as seen in the attacks and counter-attacks of the Russians and Ukrainians in this war. Contemporary military forces are still unable to see this new reality of war. When analyzing the Russian advance, it's important to consider that all these maneuvers take days to unfold, but the point is that the Russians have already adapted to this pace, not bothered whether a particular advance will take 3 weeks or 3 months. They advance continuously following tactical protocols with little threat from Ukrainian forces, which, without new equipment, have had their defensive tactics remain almost unchanged over the past two years, relying mainly on drones and making it easier for Russian studies of countermeasures. And what can Ukraine do in this situation? I see few options, but one would be to delay the Russian advance with a good number of missiles, though personally, I find it unlikely that they will reach Ukrainian hands. It wouldn't have the power to change the balance of the war, but it would guarantee more time, which is important because the battlefield is dynamic, and the implementation of new tactics based on innovative weapons can change everything overnight. A war that seems almost lost today could take a different turn in weeks. Time is crucial for Ukraine, which has fronts only about 130 km from cities like Zaporizhia and Dnipro.
0:17

Slow Progress is the New Reality of Modern Wars There are many people commenting on Russian difficulties and coming up with numerous reasons for their alleged collapse. I absolutely do not see any collapse; on the contrary, Russia has already normalized a state of war in Ukraine, which boosts its economic and industrial growth. The difficulties faced by Russia today are the same as at the beginning of the war, with soldiers having to spend up to half of their initial salaries on their own equipment, delays in pensions, and a series of other problems that are mirrored on the Ukrainian side, even with all the support from allies. The war today is much less lethal than it was months ago, and both Russian and Ukrainian losses have significantly decreased during this phase. Lethality has fallen, but Russian advances persist. And why are they slow? Is it a Ukrainian tactic? No. They are slow because they are accompanied by the deployment of communication infrastructure like signal repeaters for drones, the advancement of artillery guided by drones, maneuvers using FAB and more recently ODAB bombs against Ukrainian drone operators' facilities, infiltration by reconnaissance teams, saboteurs, and a series of protocols they have developed. That conventional war with rapid advances no longer exists, and in the context of a battlefield dominated by drones, it is unlikely to return. Modern wars will have slow progress, as seen in the attacks and counter-attacks of the Russians and Ukrainians in this war. Contemporary military forces are still unable to see this new reality of war. When analyzing the Russian advance, it's important to consider that all these maneuvers take days to unfold, but the point is that the Russians have already adapted to this pace, not bothered whether a particular advance will take 3 weeks or 3 months. They advance continuously following tactical protocols with little threat from Ukrainian forces, which, without new equipment, have had their defensive tactics remain almost unchanged over the past two years, relying mainly on drones and making it easier for Russian studies of countermeasures. And what can Ukraine do in this situation? I see few options, but one would be to delay the Russian advance with a good number of missiles, though personally, I find it unlikely that they will reach Ukrainian hands. It wouldn't have the power to change the balance of the war, but it would guarantee more time, which is important because the battlefield is dynamic, and the implementation of new tactics based on innovative weapons can change everything overnight. A war that seems almost lost today could take a different turn in weeks. Time is crucial for Ukraine, which has fronts only about 130 km from cities like Zaporizhia and Dnipro.

Patricia Marins

39,318 Aufrufe • vor 1 Jahr

Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
0:11

Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.

Anthropic

3,617,546 Aufrufe • vor 1 Tag

AI is not accelerating nearly fast enough to cure cancer. That is the problem. And it literally cannot without actually seeing what’s happening inside the cell. There’s this new project claiming their models will “solve” cancer by predicting drug responses at scale. Cool story. Except their entire approach still treats the cell like a black box. They’re optimizing for binding affinity while having zero idea what the drug actually does once it’s inside a real, living cell. Meanwhile we’re over here building the tools to watch the cell in real time. No staining or sequencing. Just direct observation of mechanism. You can simulate all you want. But if you can’t see the actual cellular response, you’re just making very confident guesses about something you’ve never actually looked at. We’ve spent two years proving this. The data is there. The difference is night and day. AI is a tool. It’s not the microscope. If your model can’t tell you why a drug is killing the wrong cells or why resistance is forming in real time… it’s not ready to cure cancer. It’s ready to waste another billion dollars. We’re not competing with AI. We’re giving it eyes. Goodbye.
0:16

AI is not accelerating nearly fast enough to cure cancer. That is the problem. And it literally cannot without actually seeing what’s happening inside the cell. There’s this new project claiming their models will “solve” cancer by predicting drug responses at scale. Cool story. Except their entire approach still treats the cell like a black box. They’re optimizing for binding affinity while having zero idea what the drug actually does once it’s inside a real, living cell. Meanwhile we’re over here building the tools to watch the cell in real time. No staining or sequencing. Just direct observation of mechanism. You can simulate all you want. But if you can’t see the actual cellular response, you’re just making very confident guesses about something you’ve never actually looked at. We’ve spent two years proving this. The data is there. The difference is night and day. AI is a tool. It’s not the microscope. If your model can’t tell you why a drug is killing the wrong cells or why resistance is forming in real time… it’s not ready to cure cancer. It’s ready to waste another billion dollars. We’re not competing with AI. We’re giving it eyes. Goodbye.

Parmita Mishra

48,203 Aufrufe • vor 1 Monat

❗️ War in the Middle East could lead to the collapse of the global economy - ship traffic through the Strait of Hormuz has almost completely stopped. ◾️ Over the past 24 hours, only two commercial vessels have passed through the Strait of Hormuz, and not a single oil tanker, the Joint Maritime Information Center said. ◾️ This is a key energy artery of the world: normally, about 20% of all oil passes through it. If tanker traffic stops, the world could lose up to 15-20 million barrels per day. ◾️ In the event of a protracted crisis, oil prices could soar to $120-150 per barrel, leading to higher fuel prices, inflation, a decline in production, and the risk of a global recession. ◾️ Europe and Asia, which are critically dependent on oil from the Persian Gulf, are already feeling the biggest impact. ◾️ Fuel flows from the Middle East have fallen by about 90%, and in Singapore, bunker fuel prices have already risen by more than 40%. In fact, the energy crisis has already begun in Asia. ◾️ More and more experts are pointing out that the Strait of Hormuz is blocked not only by war but also by insurance companies that have canceled insurance for global ocean commercial tonnage due to military risks in the Persian Gulf, the Gulf of Oman, and all Iranian territorial waters. 📹: Ship traffic in the Strait of Hormuz over the past 24 hours.
0:15

❗️ War in the Middle East could lead to the collapse of the global economy - ship traffic through the Strait of Hormuz has almost completely stopped. ◾️ Over the past 24 hours, only two commercial vessels have passed through the Strait of Hormuz, and not a single oil tanker, the Joint Maritime Information Center said. ◾️ This is a key energy artery of the world: normally, about 20% of all oil passes through it. If tanker traffic stops, the world could lose up to 15-20 million barrels per day. ◾️ In the event of a protracted crisis, oil prices could soar to $120-150 per barrel, leading to higher fuel prices, inflation, a decline in production, and the risk of a global recession. ◾️ Europe and Asia, which are critically dependent on oil from the Persian Gulf, are already feeling the biggest impact. ◾️ Fuel flows from the Middle East have fallen by about 90%, and in Singapore, bunker fuel prices have already risen by more than 40%. In fact, the energy crisis has already begun in Asia. ◾️ More and more experts are pointing out that the Strait of Hormuz is blocked not only by war but also by insurance companies that have canceled insurance for global ocean commercial tonnage due to military risks in the Persian Gulf, the Gulf of Oman, and all Iranian territorial waters. 📹: Ship traffic in the Strait of Hormuz over the past 24 hours.

Anton Gerashchenko

486,064 Aufrufe • vor 5 Monaten

🚨🇷🇺 NATO IN PANIC: RUSSIA TURNS SU-57 INTO LONG-RANGE DRONE HUNTER Russia’s top fighter may now be part of a wider shield against long-range drone and missile strikes. New photos from Akhtubinsk show a Su-57 Felon carrying external R-73 missiles and an unidentified targeting pod — pointing to a new role against long-range drones and cruise missiles threatening targets deep inside Russia. Here’s why this matters: 🔸 STRATEGIC ADAPTATION: The Su-57 demonstrates versatility by shifting to defensive missions, effectively protecting Russian airspace with its advanced systems against evolving Ukrainian long-range threats. 🔸 OPTIMIZED LOADOUT: External carriage of R-73/R-74 missiles enables rapid close-range engagements suited for slow, low-altitude drones and cruise missiles, utilizing proven short-range capabilities. 🔸 ADVANCED SENSOR SUITE: The N036 multi-array AESA radar combined with the 101KS electro-optical and IRST systems delivers superior detection and tracking of low-signature targets, enhancing counter-drone performance. 🔸 MULTI-LAYERED DEFENSE: Integrating Su-57 capabilities alongside S-400 batteries, Pantsir systems, and alert fighters provides a comprehensive response to deep strikes, maintaining robust protection over vast Russian territory. Do you think the Su-57 can help Russia counter long-range drone and cruise missile attacks?
0:15

🚨🇷🇺 NATO IN PANIC: RUSSIA TURNS SU-57 INTO LONG-RANGE DRONE HUNTER Russia’s top fighter may now be part of a wider shield against long-range drone and missile strikes. New photos from Akhtubinsk show a Su-57 Felon carrying external R-73 missiles and an unidentified targeting pod — pointing to a new role against long-range drones and cruise missiles threatening targets deep inside Russia. Here’s why this matters: 🔸 STRATEGIC ADAPTATION: The Su-57 demonstrates versatility by shifting to defensive missions, effectively protecting Russian airspace with its advanced systems against evolving Ukrainian long-range threats. 🔸 OPTIMIZED LOADOUT: External carriage of R-73/R-74 missiles enables rapid close-range engagements suited for slow, low-altitude drones and cruise missiles, utilizing proven short-range capabilities. 🔸 ADVANCED SENSOR SUITE: The N036 multi-array AESA radar combined with the 101KS electro-optical and IRST systems delivers superior detection and tracking of low-signature targets, enhancing counter-drone performance. 🔸 MULTI-LAYERED DEFENSE: Integrating Su-57 capabilities alongside S-400 batteries, Pantsir systems, and alert fighters provides a comprehensive response to deep strikes, maintaining robust protection over vast Russian territory. Do you think the Su-57 can help Russia counter long-range drone and cruise missile attacks?

NewRulesGeopolitics

17,733 Aufrufe • vor 1 Monat

❗️❗️🇺🇸🇮🇱🚀🇮🇷 The United States is reportedly preparing a new large-scale military operation against Iran, with multiple major American media outlets indicating that an intensive air campaign could begin as early as this weekend. 🔹 The Wall Street Journal: President Donald Trump has ordered the U.S. military to prepare a new attack on Iran that could begin this weekend and continue for several days. 🔹 ABC News: Trump is considering a sustained series of strikes against Iran's energy infrastructure. According to another source, the plans were discussed with Israeli officials, although it remains unclear whether Israel will directly participate. 🔹 NBC News: The United States and Israel are reportedly preparing what could become the most extensive bombing campaign yet against Iran's energy infrastructure, with operations potentially lasting throughout the weekend. 🔹 CNN: The U.S. has prepared plans for a new wave of strikes that could begin this weekend, including options targeting Iran's nuclear and energy infrastructure. According to the network, there are currently no clear indications that Israel will participate directly in this phase of the operation. 🔹 CBS News: Israeli officials have been fully briefed and remain in close coordination with Washington. Sources say discussions included completing the expanded strike campaign before financial markets reopen on Monday due to concerns over its potential impact on the U.S. and global economy. According to two U.S. officials, Iranian power plants and oil refineries are expected to be among the primary targets. A senior Israeli official also said that Trump and Netanyahu reviewed three military options, including strikes focused on Iran's strategic ground supply routes. The convergence of reporting from several major U.S. media outlets suggests that Washington is actively preparing options for a significantly broader campaign than previous operations. If such strikes are carried out, they would likely mark a major escalation aimed at degrading Iran's military and economic infrastructure while substantially increasing the risk of a wider regional confrontation. See the latest updates with us: Visioner
0:16

❗️❗️🇺🇸🇮🇱🚀🇮🇷 The United States is reportedly preparing a new large-scale military operation against Iran, with multiple major American media outlets indicating that an intensive air campaign could begin as early as this weekend. 🔹 The Wall Street Journal: President Donald Trump has ordered the U.S. military to prepare a new attack on Iran that could begin this weekend and continue for several days. 🔹 ABC News: Trump is considering a sustained series of strikes against Iran's energy infrastructure. According to another source, the plans were discussed with Israeli officials, although it remains unclear whether Israel will directly participate. 🔹 NBC News: The United States and Israel are reportedly preparing what could become the most extensive bombing campaign yet against Iran's energy infrastructure, with operations potentially lasting throughout the weekend. 🔹 CNN: The U.S. has prepared plans for a new wave of strikes that could begin this weekend, including options targeting Iran's nuclear and energy infrastructure. According to the network, there are currently no clear indications that Israel will participate directly in this phase of the operation. 🔹 CBS News: Israeli officials have been fully briefed and remain in close coordination with Washington. Sources say discussions included completing the expanded strike campaign before financial markets reopen on Monday due to concerns over its potential impact on the U.S. and global economy. According to two U.S. officials, Iranian power plants and oil refineries are expected to be among the primary targets. A senior Israeli official also said that Trump and Netanyahu reviewed three military options, including strikes focused on Iran's strategic ground supply routes. The convergence of reporting from several major U.S. media outlets suggests that Washington is actively preparing options for a significantly broader campaign than previous operations. If such strikes are carried out, they would likely mark a major escalation aimed at degrading Iran's military and economic infrastructure while substantially increasing the risk of a wider regional confrontation. See the latest updates with us: Visioner

Visioner

16,859 Aufrufe • vor 19 Tagen

The front in the Zaporizhzhia direction is collapsing Russian forces have broken through Ukrainian defenses in eastern Zaporizhzhia Oblast and advanced toward Huliaipole, according to OSINT channels. The DeepState project reports that a breakthrough near the Yanchur River allowed Russian troops to advance from the northeast, creating a threat of partial encirclement of the city. In recent weeks, Russian forces have captured dozens of square kilometers — including the villages of Sladke, Novoe, and Novonikolayevka — and begun fighting for Rovnopol, just 11 km from Huliaipole. Experts describe the situation as a “localized collapse of defenses.” Russian troops are advancing 4–5 km every few days, while Ukrainian forces struggle to fortify new positions. Military analysts warn that if this pace continues, the city could be encircled or captured within two weeks. The Armed Forces of Ukraine have confirmed difficulties in the area. Ukrainian troops withdrew from several positions near five settlements in the Huliaipole sector, said Southern Defense Forces spokesman Vladyslav Voloshyn. “We completely left Uspenivka and Novonikolayivka. Heavy fighting continues for Yablokove and three to four other locations. The defensive operation continues. The frontline remains very dynamic.” Huliaipole, once home to 13,000 people, remains a strategically important crossroads in eastern Ukraine.
0:16

The front in the Zaporizhzhia direction is collapsing Russian forces have broken through Ukrainian defenses in eastern Zaporizhzhia Oblast and advanced toward Huliaipole, according to OSINT channels. The DeepState project reports that a breakthrough near the Yanchur River allowed Russian troops to advance from the northeast, creating a threat of partial encirclement of the city. In recent weeks, Russian forces have captured dozens of square kilometers — including the villages of Sladke, Novoe, and Novonikolayevka — and begun fighting for Rovnopol, just 11 km from Huliaipole. Experts describe the situation as a “localized collapse of defenses.” Russian troops are advancing 4–5 km every few days, while Ukrainian forces struggle to fortify new positions. Military analysts warn that if this pace continues, the city could be encircled or captured within two weeks. The Armed Forces of Ukraine have confirmed difficulties in the area. Ukrainian troops withdrew from several positions near five settlements in the Huliaipole sector, said Southern Defense Forces spokesman Vladyslav Voloshyn. “We completely left Uspenivka and Novonikolayivka. Heavy fighting continues for Yablokove and three to four other locations. The defensive operation continues. The frontline remains very dynamic.” Huliaipole, once home to 13,000 people, remains a strategically important crossroads in eastern Ukraine.

NEXTA

648,483 Aufrufe • vor 9 Monaten